Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

March 31, 2021

Conditions
Childhood Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacokinetic (PK) study

Correlative studies

DRUG

Prexasertib

Given IV

Trial Locations (21)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Childrens Hospital, Phoenix

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT02808650 - Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter